why choose us

First received: November 11, 2023

Clinical Trial: Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Peripheral Neuropathy Due to Chemotherapy

Study Type: INTERVENTIONAL


Official Title: Efficacy of Losartan in the Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients.

Brief Summary: Paclitaxel-induced peripheral neuropathy (PIPN) is one of the most dose-limiting side effects; it causes patients discomfort and pain and sometimes causes the termination of the chemotherapy cycles, leading to treatment failure.A lot of interventions have been tried to prevent PIPN, ensure complete administration of the chemotherapy cycles, and increase the survival rate.One of the promising interventions in the prevention of PIPN is Losartan.Losartan is an angiotensin receptor blocker (ARBs) and is used to treat…

Read more